Old Web
English
Sign In
Acemap
>
authorDetail
>
Kirsten Orand
Kirsten Orand
City of Hope National Medical Center
Cancer research
Medicine
in patient
Obinutuzumab
Syk
4
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
2021
Blood
Alexey V. Danilov
Vi Lam
Bria Thurlow
Stephen E. Spurgeon
Byung Park
Kirsten Orand
Adam Kittai
Show All
Source
Cite
Save
Citations (0)
Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia.
2021
British Journal of Clinical Pharmacology
Vi Lam
Scott R. Best
Adam Kittai
Kirsten Orand
Stephen E. Spurgeon
Tingting Liu
Alexey V. Danilov
Show All
Source
Cite
Save
Citations (0)
A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
2021
Blood
Pallawi Torka
Swetha Kambhampati
Alexandra Muir
Kirsten Orand
Lynne Smith
Alex F. Herrera
Lionel D. Lewis
Francisco J. Hernandez-Ilizaliturri
Lu Chen
Alexey V. Danilov
Show All
Source
Cite
Save
Citations (0)
A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
2021
Blood
Geoffrey Shouse
Tanya Siddiqi
Leslie Popplewell
Alexandra Muir
Ivana Melgar
Brandy Gonzales
Kirsten Orand
Sandrine Puverel
Lili Wang
Adam Kittai
Lu Chen
Matthew S. Davids
Alexey V. Danilov
Show All
Source
Cite
Save
Citations (0)
1